Literature DB >> 6112154

Benzodiazepine antagonism by harmane and other beta-carbolines in vitro and in vivo.

H Rommelspacher, C Nanz, H O Borbe, K J Fehske, W E Müller, U Wollert.   

Abstract

Harmane and other related beta-carbolines are putative endogenous ligands of the benzodiazepine receptor. Since the compounds are potent convulsants they may have agonist activities at the benzodiazepine receptor while the benzodiazepines may be antagonists. This hypothesis was proved by comparing the in vivo and in vitro antagonism of benzodiazepines by harmane and other beta-carbolines. Harmane is clearly a competitive inhibitor of benzodiazepine receptor binding in vitro. Moreover, harmane-induced convulsions can be inhibited reversibly by diazepam in a manner which is consistent with the assumption of competitive antagonism in vivo. For some beta-carboline derivatives a correlation was found between the affinity for the benzodiazepine receptor in vitro and the convulsive potency in vivo. Thus, the data reported suggest that harmane or other related beta-carbolines are putative endogenous agonists of the benzodiazepine receptor. This suggestion is further supported by the observation that diazepam is equally potent in inhibiting harmane- or picrotoxin-induced convulsions, indicating a convulsive mechanism within the GABA receptor-benzodiazepine receptor system.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112154     DOI: 10.1016/0014-2999(81)90173-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

Review 1.  Neuroimaging insights into the role of cortical GABA systems and the influence of nicotine on the recovery from alcohol dependence.

Authors:  Kelly P Cosgrove; Irina Esterlis; Graeme F Mason; Frederic Bois; Stephanie S O'Malley; John H Krystal
Journal:  Neuropharmacology       Date:  2011-01-27       Impact factor: 5.250

2.  Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.

Authors:  A Ostergren; A Fredriksson; E B Brittebo
Journal:  J Neural Transm (Vienna)       Date:  2005-08-03       Impact factor: 3.575

3.  5-HT, dopamine, norepinephrine, and related metabolites in brain of low alcohol drinking (LAD) rats shift after chronic intra-hippocampal infusion of harman.

Authors:  A Adell; R D Myers
Journal:  Neurochem Res       Date:  1995-02       Impact factor: 3.996

4.  Comparison of the in vitro binding characteristics of the beta-carbolines harman and norharman in rat brain and liver and in bovine adrenal medulla.

Authors:  T May; A Greube; S Strauss; D Heineke; J Lehmann; H Rommelspacher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

5.  Nicotine and Nicotine Abstinence Do Not Interfere with GABAA Receptor Neuroadaptations During Alcohol Abstinence.

Authors:  Ansel T Hillmer; Tracy Kloczynski; Christine M Sandiego; Brian Pittman; Jon M Anderson; David Labaree; Hong Gao; Yiyun Huang; Giuseppe Deluliis; Stephanie S O'Malley; Richard E Carson; Kelly P Cosgrove
Journal:  Alcohol Clin Exp Res       Date:  2016-03-12       Impact factor: 3.455

6.  Two metabolic pathways of tetrahydronorharmane (tetrahydro-beta-carboline) in rats.

Authors:  B Greiner; H Rommelspacher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-04       Impact factor: 3.000

7.  Beta-carboline binding indicates the presence of benzodiazepine receptor subclasses in the bovine central nervous system.

Authors:  K J Fehske; I Zube; H O Borbe; U Wollert; W E Müller
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-05       Impact factor: 3.000

8.  β-Carbolines found in cigarette smoke elevate intracranial self-stimulation thresholds in rats.

Authors:  Andrew C Harris; Peter Muelken; Mark G LeSage
Journal:  Pharmacol Biochem Behav       Date:  2020-09-11       Impact factor: 3.533

9.  GABAA-benzodiazepine receptor availability in smokers and nonsmokers: relationship to subsyndromal anxiety and depression.

Authors:  Irina Esterlis; Kelly P Cosgrove; Jeffery C Batis; Frederic Bois; Tracy A Kloczynski; Stephanie M Stiklus; Edward Perry; Gilles D Tamagnan; John P Seibyl; Robert Makuch; Suchitra Krishnan-Sarin; Stephanie O'Malley; Julie K Staley
Journal:  Synapse       Date:  2009-12       Impact factor: 2.562

10.  Reduction of flurazepam convulsive threshold by Ro 15-1788.

Authors:  W M Bourn; R L Garrett; C E Reigel; F O Risinger
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.